CARVYKTI.COM: Keyword Density Checker

Total words: 3868 | 2-word phrases: 1001 | 3-word phrases: 1167 | 4-word phrases: 1223

PAGE INFO

Title	Try to keep the title under 60 characters (56 characters) Patient Website \| CARVYKTI® (ciltacabtagene autoleucel)
Description	Try to keep the meta description between 50 - 160 characters (139 characters) Learn about CARVYKTI®, a type of CAR-T cell therapy for adult patients. See Safety & Prescribing information, including Boxed Warning.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (63 characters) DON'T WAIT TO FIND OUT IF CARVYKTI® MAY BE RIGHT FOR YOU

#	Keyword	Frequency	Density
1	see more stories	5	0.43%
2	your healthcare provider	4	0.34%
3	your multiple myeloma	4	0.34%
4	additional therapy to	3	0.26%
5	your t cells	3	0.26%
6	white blood cells	3	0.26%
7	bridging therapy† step	3	0.26%
8	t cells are	3	0.26%
9	multiple myeloma often	3	0.26%
10	treat your multiple	3	0.26%
11	patient and care	3	0.26%
12	carvykti® is a	3	0.26%
13	treatment your doctor	3	0.26%
14	preinfusion treatment your	3	0.26%
15	healthcare provider will	3	0.26%
16	3 to 6	3	0.26%
17	cell collection and	3	0.26%
18	may prescribe additional	2	0.17%
19	and sent to	2	0.17%
20	frozen and sent	2	0.17%
21	your white blood	2	0.17%
22	and preinfusion treatment	2	0.17%
23	genetically modifying your	2	0.17%
24	to 5 weeks	2	0.17%
25	called bridging therapy†	2	0.17%
26	modifying your t	2	0.17%
27	prescribe additional therapy	2	0.17%
28	myeloma often called	2	0.17%
29	to treat your	2	0.17%
30	your doctor may	2	0.17%

#	Keyword	Frequency	Density
1	treat your multiple myeloma	3	0.25%
2	your healthcare provider will	3	0.25%
3	your multiple myeloma often	3	0.25%
4	preinfusion treatment your doctor	3	0.25%
5	multiple myeloma often called	2	0.16%
6	and outcomes of manufacturing	2	0.16%
7	timing and outcomes of	2	0.16%
8	3 to 6 hours	2	0.16%
9	called bridging therapy† step	2	0.16%
10	genetically modifying your t	2	0.16%
11	outcomes of manufacturing may	2	0.16%
12	sign up for updates	2	0.16%
13	frozen and sent to	2	0.16%
14	patients in the cartitude4	2	0.16%
15	journey see more stories	2	0.16%
16	in the cartitude4 study	2	0.16%
17	patient and care partner	2	0.16%
18	your white blood cells	2	0.16%
19	the cartitude4 study received	2	0.16%
20	modifying your t cells	2	0.16%
21	4 weeks and beyond	2	0.16%
22	between cell collection and	2	0.16%
23	your doctor may prescribe	2	0.16%
24	collection and preinfusion treatment	2	0.16%
25	2 to 3 months	2	0.16%
26	about 2 to 3	2	0.16%
27	takes about 2 to	2	0.16%
28	generally takes about 2	2	0.16%
29	and preinfusion treatment your	2	0.16%
30	treatment your doctor may	2	0.16%
31	in a clinical trial	2	0.16%
32	your carvykti® cart cells	2	0.16%
33	may prescribe additional therapy	2	0.16%
34	prescribe additional therapy to	2	0.16%
35	carvykti® certified treatment center	2	0.16%
36	additional therapy to treat	2	0.16%
37	therapy to treat your	2	0.16%
38	to treat your multiple	2	0.16%
39	multiple myeloma diagnosis and	2	0.16%
40	cartitude4 study received bridging	2	0.16%

#	URL	Whois	Check
1	https://www.carvyktihcp.com	Whois	carvyktihcp.com
2	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf	Whois	janssenlabels.com
3	https://www.janssenlabels.com/package-insert/product-patient-information/CARVYKTI-medication-guide.pdf	Whois	janssenlabels.com
4	https://www.carvyktirems.com/	Whois	carvyktirems.com
5	https://www.carvyktihcp.com/	Whois	carvyktihcp.com
6	https://www.janssen.com/oncology	Whois	janssen.com
7	https://www.legendbiotech.com	Whois	legendbiotech.com